Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Adult Vaccination Ecosystem in IndiaRelease Date:Quality Improvement Vaccines India Evidence Based Safety Contextualization of JAK inhibitors in the Treatment of Moderate to Severe Atopic DermatitisRelease Date:Education Inflammation & Immunology China, France, Germany, Italy, Japan, Korea, Spain, USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology Spain Optimizing Clinical Care Delivery for Patients with Multiple Myeloma Receiving Bispecific AntibodiesRelease Date:Quality Improvement Oncology All Enhancing HCP Education in Maternal VaccinationRelease Date:Education Vaccines Saudi Arabia Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology All Evidence-Based Education on the Potential Impact of a Generic JAK Inhibitor on the Management of Rheumatologic DiseasesRelease Date:Education Inflammation & Immunology USA B-cell Maturation Antigen (BCMA) Bi-Specific Antibodies (BsAbs) in Relapsed/Refractory Multiple Myeloma (RRMM)Release Date:Education Oncology USA Education on Mechanism of Action of JAK3 and TEC Family Kinase Role in Alopecia AreataRelease Date:Education Inflammation & Immunology USA 2026 Hemophilia Fellowship – United StatesRelease Date:Fellowship Rare Disease All Pediatric Pneumococcal Disease and Serotype Distribution: Surveillance Studies in Saudi ArabiaRelease Date:Research Vaccines Saudi Arabia Optimising Ulcerative Colitis Care: Bridging Knowledge Gaps, Integrating Biomarker-Based Strategies, and Advancing EquityRelease Date:Education Inflammation & Immunology Australia Title Grant Type Focus Area Country Application Due Date Alopecia Areata (Global)Release Date:Research Inflammation & Immunology USA Advancing Health Literacy in The Republic of IrelandRelease Date:Education Support for the Professions Ireland Education to Improve Antimicrobial Resistance (AMR) ManagementRelease Date:Partner: Japanese Society of ChemotherapyEducation Hospital Japan Education on the Appropriate Diagnosis and Treatment of Overactive Bladder or Neurogenic BladderRelease Date:Education Internal Medicine Japan Promote the Streamline and Optimization of Healthcare System to Improve Regional DisparitiesRelease Date:Partner: Japan Association for Development of Community MedicineQuality Improvement Support for the Professions Japan Novel Digital Diagnostic Approaches in Acromegaly and Sickle Cell DiseaseRelease Date:Research Rare Disease USA Establishing Regional Medical Care Coordination System for Detailed examination of the Causes of Heart FailureRelease Date:Quality Improvement Rare Disease Japan Improving Knowledge and Capability to Communicate Information on the Latest Hemophilia TreatmentsRelease Date:Education Rare Disease Japan Ulcerative Colitis (UC) ResearchRelease Date:Research Inflammation & Immunology Albania, Andorra, Australia, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Holy See (Vatican City State), Hungary, Iceland, Ireland, Israel, Italy, Korea, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, The Former Yugoslav, Malta, Moldova, Republic of, Monaco, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, San Marino, Slovakia (Slovak Republic), Slovenia, Spain, Sweden, Switzerland, Ukraine, United Kingdom Quality Improvement Grants to Support Development of Cardiac Amyloid CentersRelease Date:Quality Improvement Rare Disease USA Quantifying the Socio-Economic Burden of Disease for Dermatology Patients and CaregiversRelease Date:Research Inflammation & Immunology Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Japan, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia (Slovak Republic), Spain, Sweden, Switzerland, United Kingdom Evidence-informed treatment decisions in chronic inflammatory disordersRelease Date:Quality Improvement Inflammation & Immunology Australia